109 results
424B3
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement
4:53pm
information to support the position that the benefits of their product outweigh the risks for the management of acute pain severe enough to require an opioid … ) and certify under penalty of perjury that such holder is not a United States person as defined under the Code and is eligible for treaty benefits
424B5
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement for primary offering
4:52pm
the position that the benefits of their product outweigh the risks for the management of acute pain severe enough to require an opioid analgesic
8-K
EX-4.2
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
be entitled to the benefits of the provisions of this Section 3(e) regardless of (i) whether the Company has sufficient authorized shares of Common Stock
8-K
EX-4.3
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(e) regardless of (i
8-K
EX-10.1
2f60ckgr0t
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
8-K
EX-4.1
9d6 yo9tjs31bkxs
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
424B3
p9sha8zb0n4 r4g2v
2 Feb 24
Prospectus supplement
12:00am
8-K
EX-4.1
vpw6jye1y35zarvlq
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-4.2
fhjjp 0md
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-4.2
acd4a
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-10.1
oj9ylgc llz
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.1
ntkuccs4h9k8k
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-10.2
2bc01
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
424B4
02g20ydoh
2 Nov 23
Prospectus supplement with pricing info
9:00am